Sanofi (SNYNF) News Today $92.95 -1.53 (-1.62%) As of 03:53 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartFDA EventsFinancialsHeadlinesSEC FilingsShort InterestSustainabilityBuy This Stock SNYNF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Europe markets mixed as earnings, tariff uncertainty dominate market sentimentAugust 6 at 7:54 PM | msn.comDZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)August 3, 2025 | theglobeandmail.comSanofi outlines high single-digit sales growth for 2025 while advancing innovation pipeline and strategic acquisitionsJuly 31, 2025 | msn.comPress release: Online availability of Sanofi’s half-year financial report for 2025July 31, 2025 | finance.yahoo.comPress Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of rangeJuly 31, 2025 | finance.yahoo.comPress Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myelomaJuly 30, 2025 | uk.finance.yahoo.comSanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple SclerosisJuly 30, 2025 | msn.comDeutsche Bank Sticks to Its Hold Rating for Sanofi (SNYNF)July 24, 2025 | theglobeandmail.comPress Release: Sanofi announces extension of Blueprint tender offerJuly 17, 2025 | finance.yahoo.comKepler Capital Remains a Hold on Sanofi (SNYNF)July 13, 2025 | theglobeandmail.comFDA Grants Orphan Drug Designation To Sanofi’s (SNY) RiliprubartJuly 6, 2025 | msn.comSanofi’s (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in JapanJuly 6, 2025 | msn.comSanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP TreatmentJune 30, 2025 | finance.yahoo.comKymera’s partnerships with Sanofi and Gilead drive valueJune 27, 2025 | finance.yahoo.comSanofi (SAN.PA)June 20, 2025 | sg.finance.yahoo.comSanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating UpgradeJune 18, 2025 | seekingalpha.comSanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma TreatmentJune 17, 2025 | nasdaq.comSanofi (SNYNF) Gets a Buy from Berenberg BankJune 14, 2025 | theglobeandmail.comSanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global DemandJune 11, 2025 | finance.yahoo.comSanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty CareJune 9, 2025 | finance.yahoo.comGuggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)June 4, 2025 | theglobeandmail.comSanofi (SNYNF) Gets a Hold from Deutsche BankJune 4, 2025 | theglobeandmail.comM&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint dealJune 3, 2025 | uk.finance.yahoo.comSanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD TrialJune 1, 2025 | uk.finance.yahoo.comJ.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)June 1, 2025 | theglobeandmail.comSanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD ManagementMay 20, 2025 | finance.yahoo.comBristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuitMay 10, 2025 | msn.comGoldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)April 25, 2025 | markets.businessinsider.comSanofi proposes annual dividend of €3.92, a hike of 4.26% from prior dividendApril 24, 2025 | seekingalpha.comBarclays Keeps Their Buy Rating on Sanofi (SNYNF)April 24, 2025 | markets.businessinsider.comSanofi flunks mid-stage trial for asthma drugApril 15, 2025 | msn.comJefferies Remains a Buy on Sanofi (SNYNF)April 9, 2025 | markets.businessinsider.comGoldman Sachs upgrades Sanofi (SNYNF) to a HoldMarch 21, 2025 | markets.businessinsider.comBernstein Keeps Their Buy Rating on Sanofi (SNYNF)March 11, 2025 | markets.businessinsider.comBerenberg Bank Reaffirms Their Buy Rating on Sanofi (SNYNF)March 5, 2025 | markets.businessinsider.comDeutsche Bank Remains a Hold on Sanofi (SNYNF)March 4, 2025 | markets.businessinsider.comSanofi (SNYNF) Gets a Buy from UBSFebruary 13, 2025 | markets.businessinsider.comPress Release: Sanofi announces buy back of shares from L’OréalFebruary 3, 2025 | finance.yahoo.comSanofi’s Strong Growth Prospects and Strategic Initiatives Justify Buy RatingJanuary 31, 2025 | markets.businessinsider.comPositive Report for Sanofi (SNYNF) from DZ BANK AGJanuary 31, 2025 | markets.businessinsider.comPress Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025January 30, 2025 | finance.yahoo.comBernstein Remains a Buy on Sanofi (SNYNF)January 30, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sumitomo Dainippon Pharma Co (OtherDNPUF) and Sanofi (OtherSNYNF)January 30, 2025 | markets.businessinsider.comVigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)January 24, 2025 | seekingalpha.comUBS Sticks to Its Buy Rating for Sanofi (SNYNF)January 23, 2025 | markets.businessinsider.comJ.P. Morgan Remains a Hold on Sanofi (SNYNF)January 16, 2025 | markets.businessinsider.comSanofi (SNYNF) Gets a Buy from JefferiesDecember 18, 2024 | markets.businessinsider.comPositive Phase 3 Trial Results for Rilzabrutinib Support Buy Rating Amidst Strong Efficacy and Safety ProfileDecember 10, 2024 | markets.businessinsider.comDZ BANK AG Sticks to Its Hold Rating for Sanofi (SNYNF)October 28, 2024 | markets.businessinsider.comSanofi (SNYNF) Receives a Sell from Deutsche BankOctober 28, 2024 | markets.businessinsider.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address SNYNF Media Mentions By Week SNYNF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNYNF News Sentiment▼-0.440.38▲Average Medical News Sentiment SNYNF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNYNF Articles This Week▼21▲SNYNF Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FFNTF News Today AIMDW News Today AGNPF News Today ALST News Today AZNCF News Today AVXT News Today BCTXW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SNYNF) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNYNF Stock Alerts